Latest News

Acadia fails in attempt to expand use of antipsychotic to treat patients with depression

Acadia Pharmaceuticals reported negative results Monday from a pair of late-stage clinical trials seeking to expand the use of its antipsychotic medicine Nuplazid to patients with major depressive disorder. 

The two identically designed Phase 3 clinical trials involved 300 patients who hadn’t responded well to currently approved depression treatments. In both studies, Nuplazid failed to demonstrate an anti-depressive benefit compared to a placebo when given to patients alongside their current medicines.

Read the rest…

Source link

Related posts

Characterisation of the photosystem-I reaction centre complex


Coconut oil increases bad cholesterol


汉瑞祥和Vets First Choice宣布,依计划产生的新公司命名为Covetrus


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World